background: &beta-thalassemia; is the most common monogenic disorder in human. the (ct) polymorphism at -158 upstream region of the &gammag-globin; gene and pharmacological factors such as hydroxyurea have been reported to influence &gamma-globin; gene expression and the severity of clinical symptoms of &beta-thalassemia.; methods: in the present study, 51 &beta-thalassemia; intermediate patie...

Leishmania mexicana is a protozoan parasite that causes a disease in humans with frequent relapses after treatment. It is also highly resistant to the currently available drugs. For this reason, there is an urgent need for more effective antileishmanial drugs. Hydroxyurea, an anticancer drug, is toxic to replicating eukaryotic cells and has been proven to be effective in arresting the Leishmani...

Hydroxyurea inhibits DNA synthesis in Chinese hamster cells and is selectively toxic for cells actually in DNA synthesis (i.e., in S phase) at the time of exposure to the drug. Synchronized cells in G1 inhibited from entering S by hydroxyurea show a complex response to X-radiation. Cells become steadily more sensitive for a period of about 4 hr and then recover about a normal G1 sensitivity in ...

Background: Hydroxyurea is administered to control elevated blood counts in patients with myeloproliferative neoplasms (MPNs) reduce the risk of thrombosis and mortality. We reviewed side effects hydroxyurea, development secondary malignancies, drug resistance observed some patients.Current Concepts: The low incidences malformed births, intrauterine deaths, spontaneous abortions associated hydr...

While studying the effects of chemotherapy on glucocorticoid receptor (GR) binding levels in hematological malignancies, we observed a sizable increase in nuclear GR binding of [3H]dexamethasone in peripheral leukocytes from a chronic basophilic leukemia patient following treatment with hydroxyurea plus prednisone, but not after prednisone alone. This apparent clinical effect of hydroxyurea led...

BACKGROUND AND OBJECTIVE In the BABY HUG trial, young children with sickle cell anemia randomized to receive hydroxyurea had fewer episodes of pain, hospitalization, and transfusions. With anticipated broader use of hydroxyurea in this population, we sought to estimate medical costs of care in treated versus untreated children. METHODS The BABY HUG database was used to compare inpatient event...

BACKGROUND Adults with sickle cell anemia (HbSS) are inconsistently treated with hydroxyurea. OBJECTIVES We retrospectively evaluated the effects of elevating fetal hemoglobin with hydroxyurea on organ damage and survival in patients enrolled in our screening study between 2001 and 2010. METHODS An electronic medical record facilitated development of a database for comparison of study param...

INTRODUCTION Hydroxyurea is a standard treatment for myeloproliferative disorders because of its cytoreductive effects on all bone marrow cell lines. As a hydroxylated derivative of urea, it inhibits DNA synthesis by inactivating ribonucleotide diphosphate reductase. Hydroxyurea is generally well tolerated. However, a variety of cutaneous side effects including leg ulcers, dermatomyositis, and ...

Background: One of the most important phenotypic modifying factors for thalassemia is the presence of Xmn1 polymorphism. This retrospective study was performed to investigate the overall prevalence of Xmn1 polymorphism among Iranian β-thalassemia patients with homozygote IVSII-1mutation and to assess the relationship between Xmn1 polymorphism with patients’ hemoglobin levels and the response to...

Despite the widespread usage of hydroxyurea in the treatment of both malignant and nonmalignant diseases and a recent expansion in the recognition of its potential therapeutic applications, there have been few detailed studies of hydroxyurea's pharmacokinetic (PK) behavior and oral bioavailability. Parenteral administration schedules have been evaluated because of concerns about the possibility...